84 related articles for article (PubMed ID: 35200579)
1. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
2. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
3. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
[TBL] [Abstract][Full Text] [Related]
5. Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
Bitting RL; Tooze JA; Goodman M; Vile DC; Brown JM; Thomas CY; Neve M; Kooshki M; Addo S; Triozzi PL; Dubey P
Cancer Res Commun; 2024 Feb; 4(2):530-539. PubMed ID: 38345536
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Grivas P; Pouessel D; Park CH; Barthelemy P; Bupathi M; Petrylak DP; Agarwal N; Gupta S; Fléchon A; Ramamurthy C; Davis NB; Recio-Boiles A; Sternberg CN; Bhatia A; Pichardo C; Sierecki M; Tonelli J; Zhou H; Tagawa ST; Loriot Y
J Clin Oncol; 2024 Apr; 42(12):1415-1425. PubMed ID: 38261969
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
[TBL] [Abstract][Full Text] [Related]
8. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
9. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K; Eknert J; Öfverholm E; Papantoniou D; Jawdat F; Verbiéné I; Laurell A; Jänes E; Sandzén J; Wojtyna-Dziedzic E; Lagstam I; Söderkvist K; Costa Svedman F; Liedberg F; Bruzelius M; Fransson AS; Kjellström S; Omland LH; Pappot H; Ullén A
Clin Genitourin Cancer; 2023 Dec; 21(6):e438-e448. PubMed ID: 37308329
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
12. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
14. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
[TBL] [Abstract][Full Text] [Related]
15. Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
Wang Z; Bi H; Wang YD; Liu Q; Shao B; Li CQ; Fu C; Fu S; Shan GY; Chen A; Lv CC; Zeng Y
Actas Urol Esp (Engl Ed); 2024 May; 48(4):295-303. PubMed ID: 38160794
[TBL] [Abstract][Full Text] [Related]
16. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W; Yanagisawa T; Hashimoto M; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Miki J; Oyama Y; Abe H; Kimura T
Cancer Immunol Immunother; 2023 Apr; 72(4):841-849. PubMed ID: 36102985
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
[TBL] [Abstract][Full Text] [Related]
19. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
Díaz Acedo R; Galvan Banqueri M; Artacho Criado S; Fernández Parra EM; Jiménez Galán R; Gago Sánchez AI; Marín Pozo JF; Martínez Bautista MJ
Int J Clin Pharm; 2024 Apr; 46(2):382-389. PubMed ID: 38112892
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M; Myint ZW; Büttner T; Takeshita H; Okada Y; Lam ET; Gilbert D; Küronya Z; Tural D; Pichler R; Grande E; Crabb SJ; Kemp R; Massari F; Scagliarini S; Iacovelli R; Vau N; Basso U; Maruzzo M; Molina-Cerrillo J; Galli L; Bamias A; De Giorgi U; Zucali PA; Rizzo M; Seront E; Popovic L; Caffo O; Buti S; Kanesvaran R; Kopecky J; Kucharz J; Zeppellini A; Fiala O; Landmesser J; Ansari J; Giannatempo P; Rizzo A; Zabalza IO; Monteiro FSM; Battelli N; Calabrò F; Porta C
Cancer Immunol Immunother; 2023 Sep; 72(9):2961-2970. PubMed ID: 37248424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
